ArticleBreast cancer (Dove Medical Press)2025
Mendelian Randomization Integrating GWAS and eQTL Data Reveals DAAM1, a Potential Immune-Related Biomarker for Breast Cancer Prognosis.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The immune response plays a critical role in determining the prognosis of breast cancer (BC) patients. However, the underlying molecular mechanisms linking immune regulation to BC progression remain uncleared. This study aims to identify and functionally validate key immune-related genes that mechanistically impact on BC prognosis. Methods: We used the Mendelian randomization (MR) integrating genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data to prioritize candidate genes with a potential causal role in BC-related immune traits. This study was designed to establish a robust genetic rationale for candidate selection, minimizing false positives. Subsequent analyses focused on DAAM1, genes highlighted by the MR analysis, to explore their clinical relevance and biological functions. We validated their expression and association with immune infiltration levels using LASSO regression and patient tissue samples. Functional roles of DAAM1 were further investigated through in vitro assays based on cell proliferation, adhesion, invasion, and migration. The underlying mechanism was illustrated via Western blotting. Results: Our integrated MR analysis identified DAAM1 as a top candidate with a genetically supported link to BC immune traits. DAAM1 expression was significantly elevated in BC tissues and inversely correlated with immune infiltration levels, suggesting a role in modulating the tumor immune microenvironment. Functional experiments demonstrated that DAAM1 knockdown effectively suppressed BC cell proliferation, adhesion, invasion, and migration. Mechanistically, Western blot analysis revealed that DAAM1 promotes these malignant phenotypes potentially through activating the epithelial-mesenchymal transition (EMT) pathway. Conclusion: This study identified DAAM1 as a key immune-related prognostic biomarker in breast cancer, whose upregulation contributes to tumor progression and metastasis via EMT pathway. Our findings, elaborated in a causal inference framework, provide a mechanistic basis for DAAM1's role in BC and underscore its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.